Our best weapon against cancer may already live inside us — it just needs a little prodding. That’s the premise behind Normunity, which launched Tuesday with $65 million from investors to develop a ...

Dr. Lieping Chen, newly appointed as the United Technologies Corporation Professor in Cancer Research, focuses his research on developing new treatment options for cancer. His laboratory discovered ...

HARTFORD, Conn. (AP) — Aerospace conglomerate United Technologies Corp. says it’s donated $3 million to establish an endowed professorship at the Yale Cancer Center in New Haven Lieping Chen will be ...

Executives from Amplimmune, a biotechnology company acquired by MedImmune in 2013 for $500 million, is teaming with Yale University oncologist Lieping Chen to found NextCure, a Germantown-based ...

The Yale researcher who discovered the PD-L1 molecule and first showed its role in evasion of tumor immunity has teamed up with a veteran biotech executive to launch a precision oncology startup that ...

The American Association of Immunologists (AAI) honored Dr. Richard Flavell and Dr. Lieping Chen. Dr. Lieping Chen, left, and Dr. Richard Flavell Flavell, Sterling Professor of Immunobiology and chair ...

Normunity Inc. emerged from stealth by unveiling $65 million in series A funding and bold plans to tackle one of the critical issues in immuno-oncology. Normunity is based on the research of ...